Cargando…
Efflux drug transporters at the forefront of antimicrobial resistance
Bacterial antibiotic resistance is rapidly becoming a major world health consideration. To combat antibiotics, microorganisms employ their pre-existing defence mechanisms that existed long before man’s discovery of antibiotics. Bacteria utilise levels of protection that range from gene upregulation,...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599465/ https://www.ncbi.nlm.nih.gov/pubmed/28710521 http://dx.doi.org/10.1007/s00249-017-1238-2 |
_version_ | 1783264062466949120 |
---|---|
author | Rahman, Tahmina Yarnall, Benjamin Doyle, Declan A. |
author_facet | Rahman, Tahmina Yarnall, Benjamin Doyle, Declan A. |
author_sort | Rahman, Tahmina |
collection | PubMed |
description | Bacterial antibiotic resistance is rapidly becoming a major world health consideration. To combat antibiotics, microorganisms employ their pre-existing defence mechanisms that existed long before man’s discovery of antibiotics. Bacteria utilise levels of protection that range from gene upregulation, mutations, adaptive resistance, and production of resistant phenotypes (persisters) to communal behaviour, as in swarming and the ultimate defence of a biofilm. A major part of all of these responses involves the use of antibiotic efflux transporters. At the single cell level, it is becoming apparent that the use of efflux pumps is the first line of defence against an antibiotic, as these pumps decrease the intracellular level of antibiotic while the cell activates the various other levels of protection. This frontline of defence involves a coordinated network of efflux transporters. In the future, inhibition of this efflux transporter network, as a target for novel antibiotic therapy, will require the isolation and then biochemical/biophysical characterisation of each pump against all known and new antibiotics. This depth of knowledge is required so that we can fully understand and tackle the mechanisms of developing antimicrobial resistance. |
format | Online Article Text |
id | pubmed-5599465 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-55994652017-10-03 Efflux drug transporters at the forefront of antimicrobial resistance Rahman, Tahmina Yarnall, Benjamin Doyle, Declan A. Eur Biophys J Review Bacterial antibiotic resistance is rapidly becoming a major world health consideration. To combat antibiotics, microorganisms employ their pre-existing defence mechanisms that existed long before man’s discovery of antibiotics. Bacteria utilise levels of protection that range from gene upregulation, mutations, adaptive resistance, and production of resistant phenotypes (persisters) to communal behaviour, as in swarming and the ultimate defence of a biofilm. A major part of all of these responses involves the use of antibiotic efflux transporters. At the single cell level, it is becoming apparent that the use of efflux pumps is the first line of defence against an antibiotic, as these pumps decrease the intracellular level of antibiotic while the cell activates the various other levels of protection. This frontline of defence involves a coordinated network of efflux transporters. In the future, inhibition of this efflux transporter network, as a target for novel antibiotic therapy, will require the isolation and then biochemical/biophysical characterisation of each pump against all known and new antibiotics. This depth of knowledge is required so that we can fully understand and tackle the mechanisms of developing antimicrobial resistance. Springer International Publishing 2017-07-14 2017 /pmc/articles/PMC5599465/ /pubmed/28710521 http://dx.doi.org/10.1007/s00249-017-1238-2 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Rahman, Tahmina Yarnall, Benjamin Doyle, Declan A. Efflux drug transporters at the forefront of antimicrobial resistance |
title | Efflux drug transporters at the forefront of antimicrobial resistance |
title_full | Efflux drug transporters at the forefront of antimicrobial resistance |
title_fullStr | Efflux drug transporters at the forefront of antimicrobial resistance |
title_full_unstemmed | Efflux drug transporters at the forefront of antimicrobial resistance |
title_short | Efflux drug transporters at the forefront of antimicrobial resistance |
title_sort | efflux drug transporters at the forefront of antimicrobial resistance |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599465/ https://www.ncbi.nlm.nih.gov/pubmed/28710521 http://dx.doi.org/10.1007/s00249-017-1238-2 |
work_keys_str_mv | AT rahmantahmina effluxdrugtransportersattheforefrontofantimicrobialresistance AT yarnallbenjamin effluxdrugtransportersattheforefrontofantimicrobialresistance AT doyledeclana effluxdrugtransportersattheforefrontofantimicrobialresistance |